Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion

被引:15
作者
Dhaese, S. A. M. [1 ]
Colin, P. [2 ,3 ]
Willems, H. [1 ]
Heffernan, A. [4 ,5 ,6 ]
Gadeyne, B. [1 ]
Van Vooren, S. [7 ]
Depuydt, P. [1 ]
Hoste, E. [1 ]
Stove, V [7 ,8 ]
Verstraete, A. G. [7 ,8 ]
Lipman, J. [4 ,9 ,10 ]
Roberts, J. A. [4 ,6 ,9 ,11 ]
De Waele, J. J. [1 ]
机构
[1] Ghent Univ Hosp, Dept Crit Care Med, C Heymanslaan 10, B-9000 Ghent, Belgium
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands
[3] Univ Ghent, Lab Med Biochem & Clin Anal, Ghent, Belgium
[4] Univ Queensland, Univ Queensland Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[5] Griffith Univ, Sch Med, Southport, Qld, Australia
[6] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[7] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium
[8] Ghent Univ Hosp, Dept Lab Med, Ghent, Belgium
[9] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[10] CHU Nimes, Dept Anesthesiol & Crit Care, Nimes, France
[11] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Piperacillin; Pharmacokinetics; Critically ill; Saturation; BETA-LACTAM ANTIBIOTICS; POPULATION PHARMACOKINETIC ANALYSIS; NONLINEAR PHARMACOKINETICS; TAZOBACTAM; PHARMACODYNAMICS; QUANTIFICATION; INTERMITTENT; BOLUS;
D O I
10.1016/j.ijantimicag.2019.08.024
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients. Seventeen critically ill adult patients received continuous and intermittent infusion of piperacillin/tazobactam. Piperacillin plasma concentrations (n = 217) were analysed using population pharmacokinetic (PopPK) modelling. Post-hoc simulations were performed to evaluate the type I error rate associated with the study. Unseen data were used to validate the final model. The mean error (ME) and root mean square error (RMSE) were calculated as a measure of bias and imprecision, respectively. A PopPK model with parallel linear and non-linear elimination best fitted the data. The median and 95% confidence interval (CI) for the model parameters drug clearance (CL), volume of central compartment (V), volume of peripheral compartment (V-p) and intercompartmental clearance (Q) were 9 (7.69-11) L/h, 6.18 (4.93-11.2) L, 11.17 (7.26-12) L and 15.61 (12.66-23.8) L/h, respectively. The Michaelis-Menten constant (K-m) and the maximum elimination rate for Michaelis-Menten elimination (V-max) were estimated without population variability in the model to avoid overfitting and inflation of the type I error rate. The population estimates for K-m and V-max were 37.09 mg/L and 353.57 mg/h, respectively. The bias (ME) was -20.8 (95% CI -26.2 to -15.4) mg/L, whilst imprecision (RMSE) was 49.2 (95% CI 41.2-56) mg/L. In conclusion, piperacillin elimination is (partially) saturable. Moreover, the population estimate for K-m lies within the therapeutic window and therefore saturation of elimination should be accounted for when defining optimum dosing regimens for piperacillin in critically ill patients. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:741 / 749
页数:9
相关论文
共 50 条
  • [21] Bumetanide continuous-infusion dosing in critically ill pediatric patients
    Bulkley, Christina F.
    Johnson, Peter N.
    Henry, Emilie
    Harrison, Donald
    Lewis, Teresa V.
    Miller, Jamie L.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (17) : 1458 - +
  • [22] Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Awissi, Don-Kelena
    Beauchamp, Annie
    Hebert, Elisabeth
    Lavigne, Viviane
    Munoz, Danya Lucia
    Lebrun, Genevieve
    Savoie, Michel
    Fagnan, Mylene
    Amyot, Julie
    Tetreault, Nicolas
    Robitaille, Robert
    Varin, France
    Lavallee, Christian
    Pichette, Vincent
    Leblanc, Martine
    PHARMACOTHERAPY, 2015, 35 (06): : 600 - 607
  • [23] Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
    Felton, T. W.
    Roberts, J. A.
    Lodise, T. P.
    Van Guilder, M.
    Boselli, E.
    Neely, M. N.
    Hope, W. W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (07) : 4094 - 4102
  • [24] Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis
    Selig, Daniel J.
    DeLuca, Jesse P.
    Chung, Kevin K.
    Pruskowski, Kaitlin A.
    Livezey, Jeffrey R.
    Nadeau, Robert J.
    Por, Elaine D.
    Akers, Kevin S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (08) : 1091 - 1102
  • [25] Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
    Felton, T. W.
    McCalman, K.
    Malagon, I.
    Isalska, B.
    Whalley, S.
    Goodwin, J.
    Bentley, A. M.
    Hope, W. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) : 438 - 448
  • [26] Piperacillin penetration into tissue of critically ill patients with sepsis-Bolus versus continuous administration?
    Roberts, Jason A.
    Roberts, Michael S.
    Robertson, Thomas A.
    Dalley, Andrew J.
    Lipman, Jeffrey
    CRITICAL CARE MEDICINE, 2009, 37 (03) : 926 - 933
  • [27] What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
    Alobaid, Abdulaziz S.
    Brinkmann, Alexander
    Frey, Otto R.
    Roehr, Anka C.
    Luque, Sonia
    Grau, Santiago
    Wong, Gloria
    Abdul-Aziz, Mohd-Hafiz
    Roberts, Michael S.
    Lipman, Jeffrey
    Roberts, Jason A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (03) : 696 - 702
  • [28] Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients
    El-Haffaf, Ibrahim
    Guilhaumou, Romain
    Velly, Lionel
    Marsot, Amelie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (04) : 1502 - 1508
  • [29] Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration
    Mohlmann, Julia E.
    van Luin, Matthijs
    Uijtendaal, Esther V.
    Zahr, Noel
    Sikma, Maaike A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (12) : 3753 - 3757
  • [30] Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients
    Van Matre, Edward T.
    Cook, Aaron M.
    NEUROLOGICAL RESEARCH, 2016, 38 (09) : 786 - 791